Details for Patent: 9,566,234

✉ Email this page to a colleague

Which drugs does patent 9,566,234 protect, and when does it expire?

Patent 9,566,234 protects ARIKAYCE KIT and is included in one NDA.

This patent has forty-one patent family members in twenty-two countries.

Summary for Patent: 9,566,234

Patent landscape, scope, and claims:

Title:	Systems for treating pulmonary infections
Abstract:	Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.
Inventor(s):	Perkins; Walter (Pennington, NJ), Malinin; Vladimir (Plainsboro, NJ), Li; Xingong (Robbinsville, NJ), Miller; Brian (Hamilton, NJ), Seidel; Dominique (Munchen, DE), Holzmann; Philipp (Munchen, DE), Schulz; Harald (Tuttlingen, DE), Hahn; Michael (Krailing, DE)
Assignee:	Insmed Incorporated (Bridgewater, NJ)
Application Number:	13/899,457
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Delivery; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,566,234

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes	9,566,234	⤷ Subscribe	Y			TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,566,234

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013266400	⤷ Subscribe
Australia	2017225138	⤷ Subscribe
Australia	2019204100	⤷ Subscribe
Australia	2020204577	⤷ Subscribe
Brazil	112014029010	⤷ Subscribe
Canada	2870860	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.